View Post

OU Health Stephenson Cancer Center study emphasizes rapid surgical response to breast cancer diagnosis

In In The News by Barbara Jacoby

By: Ryan Polk, news reporter From: oudaily.com The OU Health Stephenson Cancer Center found in a new study that breast cancer patients should undergo tumor removal surgery quickly after their diagnosis to avoid the spread of cancer and tumor growth. According to a press release from OU Health, the OU Health Stephenson Cancer Center is the only National Cancer Institute-Designated …

View Post

Fulvestrant Deemed Effective as Later-Line Breast Cancer Treatment

In In The News by Barbara Jacoby

Source: Conference Coverage From: cancertherapyadvisor.com Fulvestrant was found to be effective as an early and later-line treatment for women with hormone refractory metastatic breast cancer, according to the results of a retrospective study reported at the 17th St. Gallen International Breast Cancer Conference 2021. To conduct the study, researchers reviewed the medical records of women with hormone receptor-positive metastatic breast …

View Post

Adjuvant Hormonal Therapy Adherence Low Among Commercially Insured Patients With Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Janelle Bradley From: .journalofclinicalpathways.com Adjuvant hormonal therapy adherence at 5 years are low among commercially insured patients with breast cancer, according to a recent study (JCO Oncol Pract. 2021;OP2000248. doi:10.1200/OP.20.00248). “Tamoxifen and aromatase inhibitors are used as adjuvant hormonal therapy for early-stage hormone receptor-positive (HR+) breast cancer,” wrote Hui Zhao, PhD, Department of Health Services Research, The University of …

View Post

Older Women Without Breast Cancer May Inappropriately View Certain Treatment Options as Negatively Impacting Prognosis

In In The News by Barbara Jacoby

By: Colleen Moretti From: curetoday.com Older women without hormone receptor (HR) positive breast cancer are still experiencing overtreatment despite national recommendations to omit, due to lack of reframing prognosis and education on treatment risks, according to a study published in Jama. “Positive reframing of recommendations to avoid (sentinel lymph node biopsy) and radiotherapy may be a strategy to reduce overtreatment …

View Post

New Clinical Strategy for HR-Positive Breast Cancer?

In Clinical Studies News by Barbara Jacoby

By: Charles Bankhead From: medpagetoday.com Ki67 values before, after preop endocrine therapy associated with recurrence risk Preoperative endocrine therapy with an aromatase inhibitor (AI) did not reduce the risk of breast cancer recurrence, but helped identify risk groups to guide adjuvant therapy decisions, a biomarker-supported clinical trial suggested. Preoperative letrozole or anastrozole led to a 5-year recurrence-free survival (RFS) of …

View Post

Better Outcomes for PIK3CA-Mutated TNBC vs Metastatic Breast Cancer

In In The News by Barbara Jacoby

From: oncnet.com In assessing the treatment landscape for PIK3CA-mutated breast cancer, researchers observed that patients with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative breast cancer have poorer outcomes and more resistance to chemotherapy than those with PIK3CA-mutated triple-negative breast cancer (TNBC; Ann Oncol. 2020;31[3]:377-386). Although PI3K inhibitors have been shown to improve outcomes in patients with PIK3CA-mutated, HR-positive, HER2-negative metastatic breast cancer, …

View Post

Acquired ESR1 Mutations Predict Poor Benefit from Further AI Therapy in Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Patients with hormone receptor (HR) positive metastatic breast cancer who acquired ESR1 mutations during prior aromatase inhibitor therapy had worse survival when treated with the aromatase inhibitor exemestane compared with fulvestrant, a combined analysis of the phase 3 SoFEA and EFECT trials found. The results were recently reported in Clinical Cancer Research. The EFECT …

View Post

Improving Upon Treatment Standards in HR+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Nichole Tucker From: targetedonc.com In an interview with Targeted Oncology, Erica Mayer, MD, discussed advances in the treatment landscape of HR-positive, HER2-negative breast, primarily with endocrine therapy and CDK4/6 inhibition. Treatment of metastatic hormone receptor (HR)-positive, HER2-negative breast cancer is traditionally executed with the use of endocrine therapy. With the emergence of targeted therapies for the treatment of this disease, …

View Post

Homing in on Targeted Treatment Strategies in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour From: onclive.com The fields of early-stage hormone receptor (HR)–positive and metastatic HER2-positive breast cancer have made great strides in recent years, said Neelima Denduluri, MD, and such progress could be attributed to the emergence of tailored treatment strategies and the use of HER2-directed agents, respectively. “We’re making great headway in [the treatment of patients with] breast cancer. …

View Post

S-1 Improves iDFS in HR+, HER2- Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Jason Harris From: onclive.com Adding the novel oral fluoropyrimidine derivative S-1 (Teysuno) to adjuvant endocrine therapy significantly improved invasive disease-free survival (iDFS) for Japanese patients with HR-positive, HER2-negative breast cancer, according to findings from the phase III POTENT trial presented at the 2019 San Antonio Breast Cancer Symposium (SABCS). At a median follow-up of 51.4 months, 10.6% of patients …